Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Basic Net EPS Stands At $-3.96

0

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) had an annual basic consolidated EPS of $-3.9588 for the period ended 2015-12-31. For the quarter ended 2015-12-31 which was on quarterly basis, the basic consolidated EPS reading was $-3.9588.

EPS from continuing operations

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $-3.9588 as the basic EPS from continuing operations for the annual period ended 2015-12-31. Quarterly basic EPS from continuing operations stood at $-3.9588 for the three-month period ended 2015-12-31.

EPS contribution from parent

From its parent company, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received basic EPS of $-3.9588 for the annual period ended 2015-12-31. EPS contribution from the parent company was $-3.9588 which was on quarterly basis for the period ended 2015-12-31.

Basic net EPS

A basic net EPS of $-3.96 was reported by Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for the annual period ended 2015-12-31. For the three-month period ended 2015-12-31 which was on a quarterly basis, the company’s basic net EPS stood at $-3.96.

Consolidated diluted EPS

For the period ended 2015-12-31, $-3.9588 was reported as the annual consolidated diluted EPS reading. Consolidated diluted EPS was $-3.9588 for the quarter ended 2015-12-31.

Basic diluted EPS

Diluted EPS reading from continuing operation was $-3.9588 which was on annual basis but for the period ended 2015-12-31. From continuing operations, Diluted EPS was $-3.9588 for the quarter ended 2015-12-31.

Net diluted EPS

Net diluted EPS reading was $-3.96 for the annual period ended 2015-12-31 while the net diluted EPS for the quarterly period ended 2015-12-31 stood at $-3.96.

Diluted EPS from parent

Diluted EPS of $-3.9588 was received by Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from its parent company which was for the annual period ended 2015-12-31. For the quarter ended 2015-12-31, diluted EPS contribution from the parent was $-3.9588 on quarterly basis. For the annual period ended 2015-12-31, $-3.96 was posted by Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) as net basic EPS reading.

For the quarter ended 2015-12-31, basic net EPS of $-3.96 was reported. The period ended 2015-12-31 had annual average basic shares outstanding of 36.783. But it was 36.783 for the quarter ended 2015-12-31. 36.783 and 36.783 were the diluted shares outstanding for the fiscal year ended is 2015-12-31 respectively.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 17 times, 1 visits today)